General form of registration statement for all companies including face-amount certificate companies

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.3
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]            
Net Revenue $ 2,350,386 $ 298,484 $ 7,154,429 $ 319,143 $ 2,532,499 $ 4,803
Total operating loss (1,973,864) (2,294,504) (6,006,892) (5,630,823) (7,973,228) (4,011,058)
Non-operating income (expense), net (24,417) 5,914 (54,392) 85,676 57,210 (4,140,596)
Net loss before income taxes (1,998,281) (2,288,590) (6,061,284) (5,545,147) (7,916,018) (8,151,654)
Income tax expense (2,559) (2,294) (11,650) (18,700) 20,993 2,459
Net Loss (2,000,840) (2,290,884) (6,072,934) (5,563,847) (7,937,011) (8,154,113)
Income tax expense 2,559 2,294 11,650 18,700 (20,993) (2,459)
Diagnostic R&D [Member]            
Product Information [Line Items]            
Net Revenue 1,731 14,250 8,654 14,250 19,442
Total operating loss (368,202) (436,799) (1,264,696) (1,196,428) (1,724,597) (1,524,170)
Laboratory Services [Member]            
Product Information [Line Items]            
Net Revenue 2,348,655 [1] 284,234 [1] 7,145,775 [1] 304,893 [1] 2,513,057 4,803
Total operating loss (2,150,825) (307,172) (7,423,109) (308,493) (3,769,783) (95,041)
General Corporate Activities [Member]            
Product Information [Line Items]            
Total operating loss $ (1,805,223) $ (1,849,017) $ (4,473,516) $ (4,445,045) $ (5,011,347) $ (2,396,650)
[1] The majority of the increase versus the prior year is from the acquisition of the clinical pathology laboratory on September 18, 2023.